173 related articles for article (PubMed ID: 16632435)
21. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
[TBL] [Abstract][Full Text] [Related]
22. Olive oil as a functional food: epidemiology and nutritional approaches.
Stark AH; Madar Z
Nutr Rev; 2002 Jun; 60(6):170-6. PubMed ID: 12078915
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Arteaga CL
Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
25. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
26. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
[TBL] [Abstract][Full Text] [Related]
27. The influence of different varieties of olive oil on N-methylnitrosourea(NMU)-induced mammary tumorigenesis.
Cohen LA; Epstein M; Pittman B; Rivenson A
Anticancer Res; 2000; 20(4):2307-12. PubMed ID: 10953289
[TBL] [Abstract][Full Text] [Related]
28. Strategies to target HER2/neu overexpression for cancer therapy.
Chen JS; Lan K; Hung MC
Drug Resist Updat; 2003 Jun; 6(3):129-36. PubMed ID: 12860460
[TBL] [Abstract][Full Text] [Related]
29. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells.
Menendez JA; Vellon L; Lupu R
Int J Gynecol Cancer; 2006; 16(1):219-21. PubMed ID: 16445636
[No Abstract] [Full Text] [Related]
30. Olive: fruit of peace against cancer.
Ozyilkan O; Colak D; Akcali Z; Basturk B
Asian Pac J Cancer Prev; 2005; 6(1):77-82. PubMed ID: 15780038
[TBL] [Abstract][Full Text] [Related]
31. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
32. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
36. Cardiac dysfunction associated with trastuzumab.
Smith KL; Dang C; Seidman AD
Expert Opin Drug Saf; 2006 Sep; 5(5):619-29. PubMed ID: 16907652
[TBL] [Abstract][Full Text] [Related]
37. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
[TBL] [Abstract][Full Text] [Related]
38. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
39. Effects of two highly monounsaturated oils on lipid composition and enzyme activities in rat jejunum.
Vázquez CM; Zanetti R; Santa-María C; Ruíz-Gutiérrez V
Biosci Rep; 2000 Oct; 20(5):355-68. PubMed ID: 11332598
[TBL] [Abstract][Full Text] [Related]
40. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
Shattuck DL; Miller JK; Carraway KL; Sweeney C
Cancer Res; 2008 Mar; 68(5):1471-7. PubMed ID: 18316611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
